Publication:
Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53

dc.contributor.authorZhong Y.
dc.contributor.authorKrisanapun C.
dc.contributor.authorLee S.-H.
dc.contributor.authorNualsanit T.
dc.contributor.authorSams C.
dc.contributor.authorPeungvicha P.
dc.contributor.authorBaek S.J.
dc.date.accessioned2021-04-05T03:36:14Z
dc.date.available2021-04-05T03:36:14Z
dc.date.issued2010
dc.date.issuedBE2553
dc.description.abstractPersuasive epidemiological and experimental evidence suggests that dietary flavonoids have anti-cancer activity. Since conventional therapeutic and surgical approaches have not been able to fully control the incidence and outcome of most cancer types, including colorectal neoplasia, there is an urgent need to develop alternative approaches for the management of cancer. We sought to develop the best flavonoids for the inhibition of cell growth, and apigenin (flavone) proved to be the most promising compound in colorectal cancer cell growth arrest. Subsequently, we found that pro-apoptotic proteins (NAG-1 and p53) and cell cycle inhibitor (p21) were induced in the presence of apigenin, and kinase pathways, including PKCδ and ataxia telangiectasia mutated (ATM), play an important role in activating these proteins. The data generated by in vitro experiments were confirmed in an animal study using APC MIN+ mice. Apigenin is able to reduce polyp numbers, accompanied by increasing p53 activation through phosphorylation in animal models. Our data suggest apparent beneficial effects of apigenin on colon cancer. © 2010 Elsevier Ltd. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationEuropean Journal of Cancer. Vol 46, No.18 (2010), p.3365-3374
dc.identifier.doi10.1016/j.ejca.2010.07.007
dc.identifier.issn9598049
dc.identifier.other2-s2.0-78649635941
dc.identifier.urihttps://hdl.handle.net/20.500.14740/7498
dc.rights.holderScopus
dc.subject.otherAntineoplastic agent
dc.subject.otherApigenin
dc.subject.otherATM protein
dc.subject.otherProtein
dc.subject.otherProtein kinase C gamma
dc.subject.otherProtein nag 1
dc.subject.otherProtein p21
dc.subject.otherProtein p53
dc.subject.otherUnclassified drug
dc.subject.otherAnimal experiment
dc.subject.otherAnimal model
dc.subject.otherAntineoplastic activity
dc.subject.otherArticle
dc.subject.otherCancer cell
dc.subject.otherColorectal cancer
dc.subject.otherControlled study
dc.subject.otherEnzyme activation
dc.subject.otherHuman
dc.subject.otherHuman cell
dc.subject.otherIn vitro study
dc.subject.otherLiquid chromatography
dc.subject.otherMouse
dc.subject.otherNonhuman
dc.subject.otherPriority journal
dc.subject.otherProtein expression
dc.subject.otherProtein phosphorylation
dc.subject.otherReverse transcription polymerase chain reaction
dc.subject.otherSignal transduction
dc.subject.otherTransient transfection
dc.subject.otherWestern blotting
dc.subject.otherAnimals
dc.subject.otherAntineoplastic Agents
dc.subject.otherApigenin
dc.subject.otherApoptosis
dc.subject.otherCell Proliferation
dc.subject.otherColorectal Neoplasms
dc.subject.otherCyclin-Dependent Kinase Inhibitor p21
dc.subject.otherEnzyme Inhibitors
dc.subject.otherGrowth Differentiation Factor 15
dc.subject.otherHumans
dc.subject.otherMice
dc.subject.otherPhosphorylation
dc.subject.otherPhosphotransferases
dc.subject.otherTumor Cells, Cultured
dc.subject.otherTumor Suppressor Protein p53
dc.titleMolecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-78649635941&doi=10.1016%2fj.ejca.2010.07.007&partnerID=40&md5=fbc768649884fdf97767d863c19e33a5

Files